23:58:30 EDT Thu 24 Sep 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Microbix Biosystems Inc
Symbol MBX
Shares Issued 108,747,705
Close 2020-05-12 C$ 0.355
Recent Sedar Documents

Microbix appoints Diagnostic as QAP seller in Italy

2020-05-12 07:54 ET - News Release

Mr. Cameron Groome reports

MICROBIX ANNOUNCES QUALITY PRODUCTS DISTRIBUTION AGREEMENT

Microbix Biosystems Inc. has appointed Diagnostic International Distribution SpA of Milan (D.I.D.) as distributor of its quality assessment products (QAPs) for Italy.

Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix's quality assessment products (QAPs) for Italy. As distributor, D.I.D. will provide marketing, inventory, distribution and logistical support for use of Microbix's QAPs by Italian clinical laboratories. At present, there are four dozen such QAPs across the ProceedX, RedX Floq and RedX controls trade names -- to support whole-process accuracy of tests for bacterial and viral diseases by emulating patient samples while being consistent, non-infectious, stable and cross-instrument compatible.

Based in Milan, D.I.D. is an Italian-owned-and-operated life sciences distribution company that provides clinical laboratories with access to a wide range of products relating to immunological and molecular infectious disease testing. D.I.D. services approximately 1,000 customers throughout Italy and acts as a local representative for multiple leading test and reagent suppliers, including for Bio-Rad Laboratories, COPAN Italia, ELITechGroup, and Quidel, among others.

Microbix COVID-19 controls products are available in liquid format as well as on Copan FloqSwabs, which are especially familiar to Italian clinical laboratories. Additionally, Italy is one of the Western countries that has largely converted cervical cancer screening programs to molecular HPV testing, making Microbix's exceptional line of HPV test controls a great addition to D.I.D.'s product portfolio.

Phil Casselli, senior vice-president of business development of Microbix, stated: "Italy's northern region has been very hard hit by the coronavirus, so it is important to provide our COVID-19 controls to help its testing programs. We're therefore honoured to have D.I.D., a highly respected company in the Italian community for many decades, representing our QAPs line of products. With the D.I.D. head office in Milan, and the leading global provider of patient sample collection swabs and media, COPAN Italia, less than an hour away, Microbix has the perfect partners to support provision of these important products to Italian testing labs."

Enrico Maffioli, president of D.I.D., also commented: "We're pleased to secure access to Microbix's innovative QAPs for our laboratory customers. Of course COVID testing is of intense interest currently, but there is a need to improve and ensure accuracy of all clinical diagnostic tests. The entire portfolio of Microbix QAPs will therefore be very helpful to our many customers. Training of D.I.D. staff about QAPs is under way and we are now beginning to stock this product portfolio."

About Microbix Biosystems Inc.

Microbix develops proprietary biological and technology solutions for human health and well-being, with sales now exceeding $1-million per month on average and approximately 80 skilled employees. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.